Seven Grand Managers LLC Purchases Shares of 50,000 Sionna Therapeutics, Inc. $SION

Key Points

• Seven Grand Managers LLC initiated a new position in Sionna Therapeutics, buying 50,000 shares valued at about $2.06 million in the fourth quarter.
• Several other major institutions also boosted their stakes, including Viking Global Investors, Vanguard, and Jennison Associates, signaling continued institutional interest in the stock.
• Insiders have been active sellers: two directors each sold 235,863 shares in April, and insiders have sold 1.72 million shares worth about $77.6 million over the last 90 days.

Seven Grand Managers LLC purchased a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximately $2,057,000. Seven Grand Managers LLC owned about 0.11% of Sionna Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Viking Global Investors LP grew its position in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company's stock valued at $55,436,000 after buying an additional 242,427 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company's stock valued at $48,749,000 after buying an additional 41,797 shares during the last quarter. Jennison Associates LLC grew its position in shares of Sionna Therapeutics by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company's stock valued at $45,883,000 after buying an additional 117,903 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sionna Therapeutics by 20.1% in the 4th quarter. Geode Capital Management LLC now owns 380,042 shares of the company's stock valued at $15,638,000 after buying an additional 63,478 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its position in shares of Sionna Therapeutics by 56.7% in the 2nd quarter. Soleus Capital Management L.P. now owns 376,000 shares of the company's stock valued at $6,524,000 after buying an additional 136,000 shares during the last quarter.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 235,863 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company's stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,717,760 shares of company stock worth $77,562,902. 3.90% of the stock is owned by company insiders.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $43.43 on Thursday. Sionna Therapeutics, Inc. has a one year low of $12.55 and a one year high of $48.44. The stock's 50-day moving average is $40.02 and its 200 day moving average is $39.77. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -22.50 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). On average, sell-side analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on SION. Stifel Nicolaus upped their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, May 18th. Freedom Capital lowered Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 20th. Guggenheim upped their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Citizens Jmp reiterated a "market outperform" rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday. Finally, Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.22.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.